Does the media prefer QURE or MDGL?

In the previous week, Madrigal Pharmaceuticals had 7 more articles in the media than uniQure. MarketBeat recorded 10 mentions for Madrigal Pharmaceuticals and 3 mentions for uniQure. Madrigal Pharmaceuticals' average media sentiment score of 0.82 beat uniQure's score of 0.78 indicating that Madrigal Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment uniQure 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Madrigal Pharmaceuticals 6 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor HALO or QURE?

In the previous week, Halozyme Therapeutics had 10 more articles in the media than uniQure. MarketBeat recorded 13 mentions for Halozyme Therapeutics and 3 mentions for uniQure. Halozyme Therapeutics' average media sentiment score of 1.20 beat uniQure's score of 0.78 indicating that Halozyme Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Halozyme Therapeutics 9 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive uniQure 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor QURE or ARWR?

In the previous week, Arrowhead Pharmaceuticals had 7 more articles in the media than uniQure. MarketBeat recorded 10 mentions for Arrowhead Pharmaceuticals and 3 mentions for uniQure. Arrowhead Pharmaceuticals' average media sentiment score of 0.98 beat uniQure's score of 0.78 indicating that Arrowhead Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment uniQure 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Arrowhead Pharmaceuticals 4 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger earnings & valuation, KRYS or QURE?

Krystal Biotech has higher revenue and earnings than uniQure. uniQure is trading at a lower price-to-earnings ratio than Krystal Biotech, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Krystal Biotech $389.13M 26.40 $204.83M $7.98 43.48 uniQure $16.10M 191.78 -$198.97M -$4.01 N/A

Is KRYS or QURE more profitable?

Krystal Biotech has a net margin of 54.82% compared to uniQure's net margin of -1,350.73%. Krystal Biotech's return on equity of 19.34% beat uniQure's return on equity. Company Net Margins Return on Equity Return on Assets Krystal Biotech 54.82% 19.34% 17.65% uniQure -1,350.73% -111.96% -29.01%

Does the media refer more to KRYS or QURE?

In the previous week, Krystal Biotech had 3 more articles in the media than uniQure. MarketBeat recorded 6 mentions for Krystal Biotech and 3 mentions for uniQure. Krystal Biotech's average media sentiment score of 1.32 beat uniQure's score of 0.78 indicating that Krystal Biotech is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Krystal Biotech 5 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive uniQure 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better valuation and earnings, ABVX or QURE?

uniQure has higher revenue and earnings than Abivax. Abivax is trading at a lower price-to-earnings ratio than uniQure, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Abivax N/A N/A -$380.27M -$5.21 N/A uniQure $16.10M 191.78 -$198.97M -$4.01 N/A

Is ABVX or QURE more profitable?

Abivax has a net margin of 0.00% compared to uniQure's net margin of -1,350.73%. Abivax's return on equity of -99.02% beat uniQure's return on equity. Company Net Margins Return on Equity Return on Assets Abivax N/A -99.02% -70.26% uniQure -1,350.73% -111.96% -29.01%

Does the media favor ABVX or QURE?

In the previous week, Abivax had 1 more articles in the media than uniQure. MarketBeat recorded 4 mentions for Abivax and 3 mentions for uniQure. Abivax's average media sentiment score of 1.55 beat uniQure's score of 0.78 indicating that Abivax is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Abivax 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive uniQure 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

uniQure (QURE) Competitors

$44.51 +0.04 (+0.09%)

Closing price 09/11/2026 04:00 PM Eastern

Extended Trading

$44.60 +0.09 (+0.20%)

As of 09/11/2026 07:40 PM Eastern

Compare

QURE vs. MDGL, HALO, ARWR, KRYS, and ABVX

Should you buy uniQure stock or one of its competitors? uniQure's main competitors and comparable companies include Madrigal Pharmaceuticals (MDGL), Halozyme Therapeutics (HALO), Arrowhead Pharmaceuticals (ARWR), Krystal Biotech (KRYS), and Abivax (ABVX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does uniQure compare to Madrigal Pharmaceuticals?

uniQure (NASDAQ:QURE) and Madrigal Pharmaceuticals (NASDAQ:MDGL) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, media sentiment, risk, analyst recommendations, institutional ownership, profitability, valuation and earnings.

uniQure has a beta of 0.94, indicating that its share price is 6% less volatile than the broader market. Comparatively, Madrigal Pharmaceuticals has a beta of -0.98, indicating that its share price is 198% less volatile than the broader market.

In the previous week, Madrigal Pharmaceuticals had 7 more articles in the media than uniQure. MarketBeat recorded 10 mentions for Madrigal Pharmaceuticals and 3 mentions for uniQure. Madrigal Pharmaceuticals' average media sentiment score of 0.82 beat uniQure's score of 0.78 indicating that Madrigal Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
uniQure	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Madrigal Pharmaceuticals	6 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

78.8% of uniQure shares are held by institutional investors. Comparatively, 98.5% of Madrigal Pharmaceuticals shares are held by institutional investors. 4.7% of uniQure shares are held by insiders. Comparatively, 17.6% of Madrigal Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Madrigal Pharmaceuticals has a net margin of -25.32% compared to uniQure's net margin of -1,350.73%. Madrigal Pharmaceuticals' return on equity of -56.65% beat uniQure's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
uniQure	-1,350.73%	-111.96%	-29.01%
Madrigal Pharmaceuticals	-25.32%	-56.65%	-25.53%

uniQure has higher earnings, but lower revenue than Madrigal Pharmaceuticals. Madrigal Pharmaceuticals is trading at a lower price-to-earnings ratio than uniQure, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
uniQure	$16.10M	191.78	-$198.97M	-$4.01	N/A
Madrigal Pharmaceuticals	$958.40M	12.88	-$288.28M	-$12.89	N/A

uniQure presently has a consensus price target of $65.00, indicating a potential upside of 46.03%. Madrigal Pharmaceuticals has a consensus price target of $699.64, indicating a potential upside of 30.90%. Given uniQure's higher probable upside, research analysts plainly believe uniQure is more favorable than Madrigal Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
uniQure	1 Sell rating(s)	2 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.76
Madrigal Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	15 Buy rating(s)	0 Strong Buy rating(s)	2.78

Summary

Madrigal Pharmaceuticals beats uniQure on 10 of the 16 factors compared between the two stocks.

How does uniQure compare to Halozyme Therapeutics?

Halozyme Therapeutics (NASDAQ:HALO) and uniQure (NASDAQ:QURE) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, media sentiment, valuation, profitability, earnings, risk, institutional ownership and analyst recommendations.

Halozyme Therapeutics currently has a consensus target price of $91.20, indicating a potential downside of 14.93%. uniQure has a consensus target price of $65.00, indicating a potential upside of 46.03%. Given uniQure's stronger consensus rating and higher possible upside, analysts clearly believe uniQure is more favorable than Halozyme Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Halozyme Therapeutics	1 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.62
uniQure	1 Sell rating(s)	2 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.76

Halozyme Therapeutics has a beta of 0.88, indicating that its share price is 12% less volatile than the broader market. Comparatively, uniQure has a beta of 0.94, indicating that its share price is 6% less volatile than the broader market.

Halozyme Therapeutics has a net margin of 24.86% compared to uniQure's net margin of -1,350.73%. Halozyme Therapeutics' return on equity of 260.98% beat uniQure's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Halozyme Therapeutics	24.86%	260.98%	23.91%
uniQure	-1,350.73%	-111.96%	-29.01%

Halozyme Therapeutics has higher revenue and earnings than uniQure. uniQure is trading at a lower price-to-earnings ratio than Halozyme Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Halozyme Therapeutics	$1.40B	8.71	$316.89M	$3.35	32.00
uniQure	$16.10M	191.78	-$198.97M	-$4.01	N/A

97.8% of Halozyme Therapeutics shares are owned by institutional investors. Comparatively, 78.8% of uniQure shares are owned by institutional investors. 2.5% of Halozyme Therapeutics shares are owned by insiders. Comparatively, 4.7% of uniQure shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, Halozyme Therapeutics had 10 more articles in the media than uniQure. MarketBeat recorded 13 mentions for Halozyme Therapeutics and 3 mentions for uniQure. Halozyme Therapeutics' average media sentiment score of 1.20 beat uniQure's score of 0.78 indicating that Halozyme Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Halozyme Therapeutics	9 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
uniQure	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Halozyme Therapeutics beats uniQure on 10 of the 16 factors compared between the two stocks.

How does uniQure compare to Arrowhead Pharmaceuticals?

uniQure (NASDAQ:QURE) and Arrowhead Pharmaceuticals (NASDAQ:ARWR) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their dividends, analyst recommendations, risk, media sentiment, profitability, institutional ownership, valuation and earnings.

In the previous week, Arrowhead Pharmaceuticals had 7 more articles in the media than uniQure. MarketBeat recorded 10 mentions for Arrowhead Pharmaceuticals and 3 mentions for uniQure. Arrowhead Pharmaceuticals' average media sentiment score of 0.98 beat uniQure's score of 0.78 indicating that Arrowhead Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
uniQure	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Arrowhead Pharmaceuticals	4 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

uniQure currently has a consensus target price of $65.00, suggesting a potential upside of 46.03%. Arrowhead Pharmaceuticals has a consensus target price of $99.15, suggesting a potential upside of 19.68%. Given uniQure's stronger consensus rating and higher possible upside, equities analysts clearly believe uniQure is more favorable than Arrowhead Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
uniQure	1 Sell rating(s)	2 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.76
Arrowhead Pharmaceuticals	1 Sell rating(s)	3 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.64

Arrowhead Pharmaceuticals has higher revenue and earnings than uniQure. Arrowhead Pharmaceuticals is trading at a lower price-to-earnings ratio than uniQure, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
uniQure	$16.10M	191.78	-$198.97M	-$4.01	N/A
Arrowhead Pharmaceuticals	$669.50M	17.43	-$1.63M	-$2.25	N/A

Arrowhead Pharmaceuticals has a net margin of -47.79% compared to uniQure's net margin of -1,350.73%. Arrowhead Pharmaceuticals' return on equity of -60.06% beat uniQure's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
uniQure	-1,350.73%	-111.96%	-29.01%
Arrowhead Pharmaceuticals	-47.79%	-60.06%	-17.37%

uniQure has a beta of 0.94, suggesting that its share price is 6% less volatile than the broader market. Comparatively, Arrowhead Pharmaceuticals has a beta of 1.28, suggesting that its share price is 28% more volatile than the broader market.

78.8% of uniQure shares are owned by institutional investors. Comparatively, 62.6% of Arrowhead Pharmaceuticals shares are owned by institutional investors. 4.7% of uniQure shares are owned by company insiders. Comparatively, 3.6% of Arrowhead Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Arrowhead Pharmaceuticals beats uniQure on 9 of the 16 factors compared between the two stocks.

How does uniQure compare to Krystal Biotech?

Krystal Biotech (NASDAQ:KRYS) and uniQure (NASDAQ:QURE) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their media sentiment, valuation, dividends, institutional ownership, analyst recommendations, risk, earnings and profitability.

Krystal Biotech currently has a consensus price target of $365.40, suggesting a potential upside of 5.30%. uniQure has a consensus price target of $65.00, suggesting a potential upside of 46.03%. Given uniQure's higher probable upside, analysts plainly believe uniQure is more favorable than Krystal Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Krystal Biotech	0 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.92
uniQure	1 Sell rating(s)	2 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.76

86.3% of Krystal Biotech shares are held by institutional investors. Comparatively, 78.8% of uniQure shares are held by institutional investors. 13.1% of Krystal Biotech shares are held by company insiders. Comparatively, 4.7% of uniQure shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, Krystal Biotech had 3 more articles in the media than uniQure. MarketBeat recorded 6 mentions for Krystal Biotech and 3 mentions for uniQure. Krystal Biotech's average media sentiment score of 1.32 beat uniQure's score of 0.78 indicating that Krystal Biotech is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Krystal Biotech	5 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
uniQure	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Krystal Biotech has higher revenue and earnings than uniQure. uniQure is trading at a lower price-to-earnings ratio than Krystal Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Krystal Biotech	$389.13M	26.40	$204.83M	$7.98	43.48
uniQure	$16.10M	191.78	-$198.97M	-$4.01	N/A

Krystal Biotech has a beta of 0.54, indicating that its share price is 46% less volatile than the broader market. Comparatively, uniQure has a beta of 0.94, indicating that its share price is 6% less volatile than the broader market.

Krystal Biotech has a net margin of 54.82% compared to uniQure's net margin of -1,350.73%. Krystal Biotech's return on equity of 19.34% beat uniQure's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Krystal Biotech	54.82%	19.34%	17.65%
uniQure	-1,350.73%	-111.96%	-29.01%

Summary

Krystal Biotech beats uniQure on 13 of the 17 factors compared between the two stocks.

How does uniQure compare to Abivax?

Abivax (NASDAQ:ABVX) and uniQure (NASDAQ:QURE) are both healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, valuation, profitability, analyst recommendations, dividends, media sentiment, institutional ownership and risk.

Abivax has a net margin of 0.00% compared to uniQure's net margin of -1,350.73%. Abivax's return on equity of -99.02% beat uniQure's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Abivax	N/A	-99.02%	-70.26%
uniQure	-1,350.73%	-111.96%	-29.01%

Abivax currently has a consensus target price of $156.38, suggesting a potential upside of 31.81%. uniQure has a consensus target price of $65.00, suggesting a potential upside of 46.03%. Given uniQure's higher probable upside, analysts clearly believe uniQure is more favorable than Abivax.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Abivax	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.88
uniQure	1 Sell rating(s)	2 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.76

In the previous week, Abivax had 1 more articles in the media than uniQure. MarketBeat recorded 4 mentions for Abivax and 3 mentions for uniQure. Abivax's average media sentiment score of 1.55 beat uniQure's score of 0.78 indicating that Abivax is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Abivax	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
uniQure	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

uniQure has higher revenue and earnings than Abivax. Abivax is trading at a lower price-to-earnings ratio than uniQure, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Abivax	N/A	N/A	-$380.27M	-$5.21	N/A
uniQure	$16.10M	191.78	-$198.97M	-$4.01	N/A

47.9% of Abivax shares are owned by institutional investors. Comparatively, 78.8% of uniQure shares are owned by institutional investors. 4.7% of uniQure shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Abivax has a beta of 0.96, suggesting that its stock price is 4% less volatile than the broader market. Comparatively, uniQure has a beta of 0.94, suggesting that its stock price is 6% less volatile than the broader market.

Summary

uniQure beats Abivax on 9 of the 16 factors compared between the two stocks.

Get uniQure News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding QURE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

QURE vs. The Competition

Export

Metric	uniQure	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$3.08B	$3.84B	$7.13B	$12.72B
Dividend Yield	N/A	3.63%	2.56%	11.15%
P/E Ratio	-11.10	14.25	275.24	25.29
Price / Sales	191.78	1,473.16	656.02	98.94
Price / Cash	N/A	106.68	77.04	51.44
Price / Book	13.95	15.12	10.33	6.20
Net Income	-$198.97M	-$22.86M	$3.50B	$358.50M
7 Day Performance	0.02%	-4.34%	-3.32%	-2.35%
1 Month Performance	-1.37%	-0.02%	-0.41%	-2.77%
1 Year Performance	169.92%	40.64%	19.21%	7.63%

uniQure Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
QURE uniQure	3.5253 of 5 stars	$44.51 +0.1%	$65.00 +46.0%	+162.8%	$3.08B	$16.10M	N/A	221	Gap Down
MDGL Madrigal Pharmaceuticals	3.2807 of 5 stars	$534.49 +0.3%	$699.64 +30.9%	+21.6%	$12.32B	$958.40M	N/A	915	News Coverage Positive News Insider Trade
HALO Halozyme Therapeutics	3.1791 of 5 stars	$107.20 +0.2%	$91.20 -14.9%	+38.3%	$12.14B	$1.40B	32.00	423	Insider Trade
ARWR Arrowhead Pharmaceuticals	2.5181 of 5 stars	$82.85 +0.1%	$99.15 +19.7%	+178.8%	$11.66B	$829.45M	N/A	711	Analyst Forecast
KRYS Krystal Biotech	3.1574 of 5 stars	$347.00 +0.4%	$365.40 +5.3%	+140.4%	$10.23B	$389.13M	43.48	295	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:QURE) was last updated on 9/12/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

uniQure (QURE) Competitors

QURE vs. MDGL, HALO, ARWR, KRYS, and ABVX

How does uniQure compare to Madrigal Pharmaceuticals?

Summary

How does uniQure compare to Halozyme Therapeutics?

Summary

How does uniQure compare to Arrowhead Pharmaceuticals?

Summary

How does uniQure compare to Krystal Biotech?

Summary

How does uniQure compare to Abivax?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

QURE vs. The Competition

uniQure Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

uniQure (QURE) Competitors

QURE vs. MDGL, HALO, ARWR, KRYS, and ABVX

How does uniQure compare to Madrigal Pharmaceuticals?

Which has more volatility & risk, QURE or MDGL?

Does the media prefer QURE or MDGL?

Do institutionals and insiders have more ownership in QURE or MDGL?

Is QURE or MDGL more profitable?

Which has stronger earnings & valuation, QURE or MDGL?

Do analysts prefer QURE or MDGL?

Summary

How does uniQure compare to Halozyme Therapeutics?

Do analysts rate HALO or QURE?

Which has more risk & volatility, HALO or QURE?

Is HALO or QURE more profitable?

Which has higher valuation and earnings, HALO or QURE?

Do insiders and institutionals have more ownership in HALO or QURE?

Does the media favor HALO or QURE?

Summary

How does uniQure compare to Arrowhead Pharmaceuticals?

Does the media favor QURE or ARWR?

Do analysts prefer QURE or ARWR?

Which has higher earnings & valuation, QURE or ARWR?

Is QURE or ARWR more profitable?

Which has more risk & volatility, QURE or ARWR?

Do institutionals and insiders hold more shares of QURE or ARWR?

Summary

How does uniQure compare to Krystal Biotech?

Do analysts recommend KRYS or QURE?

Do insiders and institutionals believe in KRYS or QURE?

Does the media refer more to KRYS or QURE?

Which has stronger earnings & valuation, KRYS or QURE?

Which has more risk & volatility, KRYS or QURE?

Is KRYS or QURE more profitable?

Summary

How does uniQure compare to Abivax?

Is ABVX or QURE more profitable?

Do analysts prefer ABVX or QURE?

Does the media favor ABVX or QURE?

Which has better valuation and earnings, ABVX or QURE?

Do insiders & institutionals hold more shares of ABVX or QURE?

Which has more volatility and risk, ABVX or QURE?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

QURE vs. The Competition

uniQure Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools